2.2 Obstructive Sleep Apnea, Cardiovascular & Metabolic Risk Stratification

Obstructive Sleep Apnea (OSA) Screening: The STOP-BANG Instrument

Obstructive Sleep Apnea (OSA) is a common, underdiagnosed sleep-related breathing disorder characterized by repetitive partial (hypopnea) or complete (apnea) collapse of the upper airway during sleep, resulting in arterial hypoxemia, hypercapnia, and frequent micro-arousals. In the ambulatory surgical population, undiagnosed or severe OSA presents profound perioperative dangers. General anesthetics, sedatives, and systemic opioids cause pharyngeal muscle relaxation, depress central ventilatory drive, and impair arousal reflexes, dramatically amplifying airway collapsibility.

Patients with unrecognized or poorly managed OSA face significantly higher rates of difficult mask ventilation, failed intubation, postanesthetic laryngospasm, severe desaturation, unplanned endotracheal re-intubation, myocardial ischemia, and fatal respiratory arrest in the Post-Anesthesia Care Unit (PACU) or at home.

The STOP-BANG Questionnaire

To rapidly and reliably identify patients at risk for OSA during preoperative screening, ambulatory surgical centers utilize the STOP-BANG questionnaire, an 8-item, scoring instrument validated by the Society of Anesthesia and Sleep Medicine and the American Society of Anesthesiologists (ASA):

• S – Snoring: Do you snore loudly (loud enough to be heard through closed doors, or your bed partner elbows you for snoring at night)?
• T – Tiredness: Do you often feel tired, fatigued, or sleepy during daytime (such as falling asleep while driving, watching television, or talking)?
• O – Observed Apnea: Has anyone observed you stop breathing, choking, or gasping during your sleep?
• P – Blood Pressure: Do you have or are you currently being treated for high blood pressure (arterial hypertension)?
• B – Body Mass Index (BMI): Is your Body Mass Index greater than 35 kg/m²?
• A – Age: Are you older than 50 years of age?
• N – Neck Circumference: Is your neck circumference greater than 17 inches (43 cm) for men, or greater than 16 inches (41 cm) for women? (Measured at the level of the cricothyroid membrane).
• G – Gender: Are you of male gender?

STOP-BANG Scoring Interpretation and Risk Stratification

Each positive response scores 1 point (total score range: 0 to 8 points):

• Low Risk of OSA: Total score of 0 to 2 points. High negative predictive value; patient can proceed with standard ambulatory anesthetic protocols.
• Intermediate Risk of OSA: Total score of 3 to 4 points. Moderate risk; warrants proactive airway planning, regional anesthesia preference, and cautious opioid titration.
• High Risk of OSA: Total score of 5 to 8 points.
  • Alternative High-Risk Criteria: A patient also classifies as High Risk if they answer "Yes" to 2 or more of the 4 STOP questions PLUS meet at least one of three specific demographic thresholds:
    1. Male gender (STOP ≥ 2 + Male)
    2. BMI > 35 kg/m² (STOP ≥ 2 + BMI > 35)
    3. Neck circumference > 17 inches in men or > 16 inches in women (STOP ≥ 2 + Neck)

Ambulatory Anesthetic & PACU Management for OSA Patients

The Society for Ambulatory Anesthesia (SAMBA) consensus guidelines emphasize that diagnosed or high-risk OSA is not an absolute contraindication to freestanding ambulatory surgery, provided the patient's comorbid systemic diseases (e.g., heart failure, pulmonary hypertension) are optimized and specific airway safety protocols are strictly enacted.

Preoperative Protocols

• CPAP Machine Compliance: Patients with established OSA treated with Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP) must be instructed during the preoperative phone assessment to bring their personal CPAP/BiPAP device, power cords, tubing, and mask to the ASC on the day of surgery.
• The ambulatory nurse inspects the machine upon arrival, confirms that the settings match the prescribed therapeutic pressures, and ensures that biomedical engineering check-in (or facility electrical safety inspection) is completed if required by facility policy.
• The device is placed at the patient's bedside in the preoperative bay and transferred directly with the patient to the PACU.

Intraoperative Anesthetic Strategies

• Anesthetic Technique Preference: Regional, neuraxial (spinal/epidural), or peripheral nerve blocks are strongly preferred over general anesthesia. When peripheral nerve blocks are employed, supplemental intravenous sedation should be minimized to avoid loss of pharyngeal muscle tone.
• Airway Management: If general anesthesia is unavoidable, endotracheal intubation with a cuffed tube is generally preferred over a supraglottic airway (LMA) in high-risk patients with difficult airway anatomy. Video laryngoscopy should be immediately available.
• Multimodal Opioid-Sparing Analgesia: High-dose systemic opioids act synergistically with residual volatile anesthetics to induce central apnea and upper airway collapse. Anesthesia providers utilize non-opioid analgesics: intravenous acetaminophen (1,000 mg IV), nonsteroidal anti-inflammatory drugs (ketorolac 15–30 mg IV or celecoxib 200 mg PO pre-op), dexamethasone (4–8 mg IV for both anti-inflammatory pain reduction and PONV prophylaxis), and surgical site local anesthetic infiltration.
• Complete Neuromuscular Blockade Reversal: Residual neuromuscular weakness severely exacerbates airway obstruction. Objective quantitative train-of-four (TOF) monitoring must demonstrate a TOF ratio > 0.9 before extubation. Sugammadex is preferentially utilized for rapid, complete reversal of rocuronium or vecuronium-induced neuromuscular blockade.

Postoperative PACU Recovery Standards

• Patient Positioning: Patients must never be placed flat supine during recovery. Elevate the head of the bed to 30 to 45 degrees (semi-Fowler position) or place the patient in a lateral recovery position to maintain gravitational forward displacement of the tongue and soft palate.
• Immediate Postoperative CPAP: If the patient was using CPAP at home or exhibits snoring, airway obstruction, or oxygen desaturation upon emergence, apply their personal CPAP machine immediately in Phase I PACU.
• Extended Phase II PACU Monitoring: High-risk OSA patients must remain in the ASC under continuous pulse oximetry and capnography monitoring for an extended period—typically at least 60 to 120 minutes longer than conventional patients, and for a minimum of 60 minutes after the last administration of any intravenous or parenteral opioid.
• Discharge Readiness: The patient must demonstrate the ability to maintain baseline oxygen saturation (SpO2 ≥ 92%–94% on room air, or at their documented home oxygen baseline) while resting quietly in an unaroused, sleep-like state. If a patient experiences recurrent respiratory depression, severe oxygen desaturation (<90% despite supplemental oxygen), or frequent obstructive episodes requiring vigorous physical stimulation, the nurse must halt discharge and initiate transfer to an acute care hospital for continuous overnight monitoring.

Cardiovascular Risk Stratification & Functional Capacity (METs)

Cardiovascular complications—including perioperative myocardial infarction, acute heart failure, malignant dysrhythmias, and stroke—represent the leading cause of catastrophic morbidity and mortality associated with non-cardiac surgery. In freestanding ambulatory surgery centers, where immediate access to cardiac catheterization laboratories and intensive care units is absent, identifying patients with occult or active cardiovascular compromise is vital.

The American College of Cardiology / American Heart Association (ACC/AHA) perioperative guidelines establish a risk stratification paradigm based on functional capacity, clinical risk factors, and procedural invasiveness.

Functional Capacity Assessment: The 4-MET Benchmark

Functional capacity is an exceptionally sensitive, validated clinical predictor of perioperative cardiopulmonary reserve and postoperative outcomes. Functional capacity is quantified in Metabolic Equivalents of Task (METs), where 1 MET represents the resting oxygen consumption of an average adult at rest (approximately 3.5 mL of oxygen per kilogram of body weight per minute [3.5 mL O2/kg/min]).

The ambulatory nurse assesses functional capacity during the preoperative health history by interviewing the patient regarding their ability to perform activities of daily living, utilizing the Duke Activity Status Index (DASI) framework:

• 1 MET: Eating, dressing, using the toilet, or sitting quietly at a desk.
• 4 METs (The Critical Clinical Cutoff): Walking on level ground at 4.0 miles per hour (6.4 km/h), walking up a slight hill, climbing a flight of stairs (approximately 8 to 12 steps) without stopping, raking leaves, scrubbing floors, or carrying a bag of groceries.
• >4 to 10 METs: Performing strenuous activities, such as climbing multiple flights of stairs rapidly, jogging, swimming laps, singles tennis, or heavy outdoor labor (digging, shoveling snow).

Clinical application: Functional capacity of 4 METs or more without limiting symptoms is reassuring, but it does not replace evaluation of active disease, procedure risk, and validated risk tools. Poor or unknown capacity prompts structured assessment. Obtain stress testing, echocardiography, or cardiology consultation only when indicated and when the result is expected to change perioperative management; routine testing of every patient below 4 METs is not recommended.

Active Cardiovascular Conditions and Timing After PCI

Postpone elective surgery and obtain appropriate evaluation for acute coronary syndrome, decompensated heart failure, unstable clinically significant arrhythmia, or severe symptomatic valvular disease. The decision also considers the ASC’s monitoring and rescue capability rather than applying ASA class or one symptom in isolation.

For prior PCI, document the indication, date, stent type when known, antiplatelet plan, and cardiology recommendations:

• After balloon angioplasty without a stent, delay elective surgery for at least 14 days.
• After a drug-eluting stent placed for acute coronary syndrome, delay elective noncardiac surgery that requires interruption of one or more antiplatelet agents for at least 12 months when possible.
• After a drug-eluting stent placed for chronic coronary disease, delaying elective surgery for at least 6 months is reasonable. Time-sensitive surgery may be considered at least 3 months after PCI when delaying surgery presents greater risk.
• Surgery requiring interruption of antiplatelet therapy within 30 days of any recent stent is potentially harmful because of stent-thrombosis risk.

Do not instruct a patient to stop aspirin or a P2Y12 inhibitor independently. The surgeon, anesthesia professional, cardiologist, and patient balance bleeding, thrombosis, and urgency and document the shared plan.

Metabolic & Endocrine Screening: Perioperative Glycemic Management

Metabolic and endocrine dysregulation—predominantly diabetes mellitus—affects a vast portion of the surgical population. In the ambulatory surgery center, perioperative hyperglycemia and acute hypoglycemia pose immediate safety threats. Intraoperative and postoperative hyperglycemia suppresses neutrophil phagocytic function, increases surgical site infection (SSI) rates, impairs collagen deposition and wound tensile strength, induces osmotic diuresis leading to hypovolemia and electrolyte imbalances, and worsens ischemic cerebral and myocardial injury. Conversely, acute hypoglycemia (blood glucose < 70 mg/dL [3.9 mmol/L]) under general anesthesia is masked by hypnosis, blunting autonomic adrenergic warning signs (tremor, diaphoresis, tachycardia) and risking permanent neuroglycopenic brain injury.

Glycemic Targets and Hemoglobin A1c Thresholds

• Preoperative Fasting Blood Glucose Target: The consensus target for diabetic patients presenting for ambulatory surgery is 100 to 180 mg/dL (5.6 to 10.0 mmol/L).
• Action Threshold for Hyperglycemia (>200 mg/dL): Blood glucose levels between 200 and 300 mg/dL require clinical evaluation, assessment of morning medication compliance, and subcutaneous administration of a rapid-acting insulin analog (e.g., insulin lispro or aspart) per facility-approved sliding scale or corrective protocol, with re-checking prior to surgical incision.
• Cancellation Thresholds (>300–400 mg/dL): A fasting blood glucose > 300 mg/dL with detectable urine or serum ketones, or any blood glucose > 400 mg/dL, warrants immediate cancellation of elective surgery and immediate medical referral for evaluation of Diabetic Ketoacidosis (DKA) or Hyperosmolar Hyperglycemic State (HHS).
• Glycated Hemoglobin (HbA1c) Recommendation: Professional consensus guidelines strongly recommend a recent (within 3 months) HbA1c < 8.0% for elective ambulatory surgical procedures. While an elevated HbA1c in isolation is not an automatic day-of-surgery cancellation trigger, an HbA1c > 8.0%–8.5% reflects chronic poor glycemic control and warrants proactive primary care or endocrinology collaboration to optimize glycemic regimens prior to elective intervention.

Day-of-Surgery Diabetic Medication Adjustments

Preoperative patient instructions regarding morning diabetic medications must follow strict evidence-based protocols to avoid hypoglycemia while patients are strictly NPO (nothing by mouth):

• Nutritional / Short-Acting Insulin (Regular, Lispro, Aspart, Glulisine): Patients must HOLD their morning dose of short-acting or rapid-acting insulin while NPO on the day of surgery, as there is no caloric intake to balance nutritional insulin.
• Basal / Long-Acting Insulin (Glargine, Detemir, Degludec): Basal insulin suppresses hepatic gluconeogenesis and lipolysis, preventing ketoacidosis. Patients should be instructed to administer 50% to 75% (or 70%–80%) of their usual basal dose on the evening prior to or morning of surgery, as determined by facility anesthesia protocols.
• Intermediate-Acting Insulin (NPH): Instruct the patient to take 50% of their usual morning NPH dose with a subcutaneous injection upon waking.
• Continuous Subcutaneous Insulin Infusions (Insulin Pumps): Patients should maintain their basal rate at 80% to 100% of their normal baseline rate; bolus doses for correction should only be delivered in consultation with the anesthesia team.
• Oral Hypoglycemics (Sulfonylureas & Meglitinides): Agents that stimulate pancreatic beta-cell insulin secretion (e.g., glipizide, glimepiride, glyburide, repaglinide) must be HELD on the morning of surgery due to the high risk of prolonged fasting hypoglycemia.
• Metformin: Instruct the patient to hold metformin on the morning of surgery. If the patient is undergoing a procedure requiring iodinated intravenous contrast or if significant renal hypoperfusion is anticipated, metformin must be held for 48 hours post-procedure and resumed only after normal renal function is confirmed, avoiding contrast-induced lactic acidosis.
• SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin): Sodium-glucose cotransporter-2 (SGLT2) inhibitors carry an FDA-mandated warning for euglycemic Diabetic Ketoacidosis (euDKA)—a life-threatening condition in which profound ketoacidosis occurs with near-normal blood glucose levels (<250 mg/dL). Surgical physiological stress, hypovolemia, and fasting trigger severe lipolysis and ketogenesis while the drug continues to excrete glucose in the urine. Professional guidelines require holding SGLT2 inhibitors for 3 to 4 days prior to elective surgery.
• GLP-1 and dual GIP/GLP-1 therapies: Current multi-society guidance allows most stable, asymptomatic patients to continue therapy. Screen for dose escalation, higher doses, nausea, vomiting, abdominal pain, constipation, bloating, and other disorders that delay gastric emptying. For elevated risk, the team may use a 24-hour liquid-only diet, point-of-care gastric ultrasound, anesthesia-plan modification, or delay. Coordinate any withholding with the prescriber and diabetes plan rather than applying a universal daily or weekly hold.